He still is. As for the quote GRTS's GRANITE-001 (personalised) PhI/II trial (n=214) is open and enrolling patients. SLATE-001 (KRAS) PhI/II (n=144) is expected to enroll patients mid-year.
The company has its own selection [1,2] and delivery platforms. For the latter, they are using a heterologous prime-boost regime [3]. By administering the same neoantigens through different delivery methods you induce greater numbers of antigen specific T-cells and increase the quality of response by involving multiple subsets with different cytokine profiles compared with homologous boosting alone. In NHPs, this induces a T-cell response comparable to clinically efficacious adoptive cell transfer treatments.
In addition, they have a partnership with BLUE [4] and hope to create the largest library of shared neoantigens in the world. I won't bore you about NTGN.
News 
Market Data 
Discover 
